While biologic therapies targeting tumor necrosis factor-alpha (anti-TNFα) are the current mainstay in both inflammatory bowel disease (IBD) and various autoimmune conditions, there is no “gold standard” for the assessment of anti-TNFα therapeutic efficacy. Here, TNF is linked to inflammatory bowel disease.